Suppr超能文献

小儿心脏手术中德尔尼多停搏液后的心肌保护

Myocardial protection following del Nido cardioplegia in pediatric cardiac surgery.

作者信息

Panigrahi Debasish, Roychowdhury Saibal, Guhabiswas Rahul, Rupert Emmanuel, Das Mrinalendu, Narayan Pradeep

机构信息

1 Department of Cardiac Anesthesia, NH Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, India.

2 Department of Cardiac Surgery, NH Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, India.

出版信息

Asian Cardiovasc Thorac Ann. 2018 May;26(4):267-272. doi: 10.1177/0218492318773589. Epub 2018 Apr 18.

Abstract

Background This study was designed to compare myocardial protection with del Nido cardioplegia and conventional blood cardioplegia in children undergoing cardiac surgery in Risk Adjustment for Congenital Heart Surgery categories 1 and 2. Methods Sixty patients were randomized into 2 groups receiving del Nido cardioplegia solution or conventional blood cardioplegia. Myocardial injury was assessed using biochemical markers (troponin I and creatine kinase-MB). Vasoactive-inotropic scores were calculated to compare inotropic requirements. Results Demographic characteristics, cardiopulmonary bypass time, and aortic crossclamp time were comparable in the 2 groups. Time-related changes in troponin I and creatine kinase-MB were similar in both groups. Statistically significant differences were seen in total cardioplegia volume requirement ( p < 0.0001), number of cardioplegia doses given ( p < 0.0001), packed red cell volume usage during cardiopulmonary bypass ( p < 0.02), and time taken to restore spontaneous regular rhythm ( p < 0.0001). Vasoactive-inotropic scores on transfer to the intensive care unit ( p < 0.040) and at 24 h ( p < 0.030) were significantly lower in the del Nido group. Duration of mechanical ventilation, intensive care unit stay, and hospital stay were comparable in the 2 groups. Conclusions Our results show that del Nido cardioplegia solution is as safe as conventional blood cardioplegia. Moreover, it provides the benefits of reduced dose requirement, lower consumption of allogenic blood on cardiopulmonary bypass, quicker resumption of spontaneous regular cardiac rhythm, and less inotropic support requirement on transfer to the intensive care unit and at 24 h, compared to conventional blood cardioplegia.

摘要

背景 本研究旨在比较在先天性心脏病手术风险调整分类1和2类的心脏手术患儿中,使用德尔尼多停搏液与传统血液停搏液进行心肌保护的效果。方法 将60例患者随机分为两组,分别接受德尔尼多停搏液或传统血液停搏液。使用生化标志物(肌钙蛋白I和肌酸激酶-MB)评估心肌损伤。计算血管活性-正性肌力评分以比较正性肌力药物的需求。结果 两组患者的人口统计学特征、体外循环时间和主动脉阻断时间具有可比性。两组肌钙蛋白I和肌酸激酶-MB的时间相关变化相似。在总停搏液体积需求(p<0.0001)、停搏液给药次数(p<0.0001)、体外循环期间浓缩红细胞体积使用量(p<0.02)以及恢复自发规则心律所需时间(p<0.0001)方面存在统计学显著差异。在转入重症监护病房时(p<0.040)和24小时时(p<0.030),德尔尼多组的血管活性-正性肌力评分显著更低。两组的机械通气时间、重症监护病房住院时间和住院时间具有可比性。结论 我们的结果表明,德尔尼多停搏液与传统血液停搏液一样安全。此外,与传统血液停搏液相比,它具有减少剂量需求、降低体外循环时异体血消耗量、更快恢复自发规则心律以及在转入重症监护病房时和24小时时减少正性肌力支持需求等优点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验